<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00499343</url>
  </required_header>
  <id_info>
    <org_study_id>ID03-0242</org_study_id>
    <nct_id>NCT00499343</nct_id>
  </id_info>
  <brief_title>G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients</brief_title>
  <official_title>A Randomized Study Comparing Chemotherapy Followed by G-CSF Alone Versus G-CSF Plus GM-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:

        1. To determine the efficacy of in vivo purging achieved by rituximab in the two groups.

        2. To determine the number of apheresis procedures, total stem cell yield/kg patient body
           weight and the toxicity profile in the two groups.

      Secondary Objectives:

        1. To determine the degree of expression of various adhesion molecules in the 2 groups and
           correlate with time to engraftment of neutrophils, platelets, and red blood cells,
           efficacy of stem cell mobilization and purging.

        2. To determine the incidence of disease progression/relapse at 12 months in the two
           groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Granulocyte-colony stimulating factor (G-CSF) and granulocyte macrophage-colony stimulating
      factor (GM-CSF) are synthetic (man-made) versions of substances naturally produced in your
      body. These substances, called colony stimulating factors, help the bone marrow to make new
      white blood cells. When certain cancer medicines fight your cancer cells, they also affect
      those white blood cells that fight infection. To help decrease the risk of infections when
      these cancer medicines are used, colony stimulating factors may be given. Colony stimulating
      factors are also used to help the bone marrow recover after bone marrow transplantation and
      stem cell transplantation. They are also used to increase the stem cell count in the blood so
      that adequate number of stem cells can be collected for purposes of transplantation.

      Before the study begins, you will have a complete physical exam and have blood (around 1-2
      tablespoons) and urine collected for routine tests. You will have x-rays and CT scans to
      check on the status of the disease. A sample of bone marrow will be collected for tests. To
      collect a bone marrow sample, an area of the hip or chest bone is numbed with anesthetic and
      a small amount of bone marrow is withdrawn through a large needle. Your heart and lung
      function will be evaluated. You will have an electrocardiogram (ECG - a test that measures
      the electrical activity of the heart) and either a echocardiogram or a multigated acquisition
      scan (MUGA) (these are tests that measure heart functions). You will also have lung function
      tests. Women who are able to have children must have a negative blood or urine pregnancy
      test.

      You will have a plastic tube (central venous catheter - CVL) inserted under your collarbone.
      The CVL will be left in place for the duration of the treatment. The catheter will be used to
      deliver most of the drugs and for the collection and transfusion of the stem cells. When
      possible, all drugs that need to be given by vein will be given using the catheter.

      All treatment will be given at M. D. Anderson. First, you will be given chemotherapy to
      increase the number of stem cells in your blood stream. This chemotherapy will include the
      drugs ifosfamide, etoposide, and rituximab. You will receive a higher dose of rituximab than
      is standard of care. The drug ifosfamide will be started on Day 2 and will be given as a
      continuous injection into a vein over 72 hours. The drug etoposide will also be started on
      Day 2 and will be given by vein over 2 hours every 12 hours. Rituximab will be given by vein
      over 4-6 hours on Days 1 and 8. To help decrease the risk of developing side effects caused
      by the chemotherapy, you will be given fluids by vein and a drug called mesna. Mesna will be
      given by vein over 24 hours after treatment with ifosfamide is finished. You will have to
      stay in the hospital for 4-6 days for this part of the treatment.

      You will be randomly assigned (as in the toss of a coin) to one of two treatment groups.
      Participants in one group will receive G-CSF and GM-CSF. Participants in the other group will
      receive G-CSF alone.

      After completion of chemotherapy, you will get GM-CSF and G-CSF or just G-CSF injections
      (given under the skin) twice a day. These drugs are given to help increase the number of
      white blood cells and will continue to be given until an adequate number of stem cells have
      been collected. During this time, you will have blood collected for tests (around 1
      tablespoon) at least 3 times a week. If your doctor feels it is necessary, you may have blood
      collected more often.

      Blood stem cells will be collected when your blood counts have returned to normal (about
      10-16 days after the chemotherapy). The process of stem cell collection takes about 4 hours.
      It may take 1-6 sessions to collect the number of stem cells needed for the transplant. The
      process of stem cell collection is called apheresis. A machine is attached to the catheter
      under the collar bone and blood is withdrawn. The blood then flows through the machine, which
      removes stem cells from the blood. The blood is then returned back to you through the
      catheter. The stem cells are then frozen and stored. These stem cells will be given back to
      you after the next phase of treatment to help your blood counts recover after high dose
      chemotherapy. After enough stem cells have been collected, you will be admitted to the
      hospital for high dose chemotherapy.

      You will have check-up visits at various times over the next year as part of your standard
      evaluation after transplantation to check on the status of the disease.

      This is an investigational study. All of the drugs used in this study are FDA approved and
      are commercially available. Up to 100 patients will take part in this study. All will be
      enrolled at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD34+ Cells/kg in Blood Stem Cells</measure>
    <time_frame>The process of stem cell collections take about 4 hours, 1-6 sessions may be needed.</time_frame>
    <description>After blood counts return to normal, stem cell collection (takes approximately 4 hours) up to 6 sessions.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Rituximab + Ifosfamide + Etoposide + 2 Growth Factors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Growth Factors = granulocyte-colony stimulating factor (G-CSF) + granulocyte macrophage-colony stimulating factor (GM-CSF)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab + Ifosfamide + Etoposide + 1 Growth Factor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Growth Factor = granulocyte-colony stimulating factor (G-CSF)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>150 mg/m^2 given intravenously over 2 hours every 12 hours x 6 doses.</description>
    <arm_group_label>Rituximab + Ifosfamide + Etoposide + 2 Growth Factors</arm_group_label>
    <arm_group_label>Rituximab + Ifosfamide + Etoposide + 1 Growth Factor</arm_group_label>
    <other_name>Vepesid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>Starting dose on day +6 at 6 mcg/kg injection every 12 hours until completion of apheresis.</description>
    <arm_group_label>Rituximab + Ifosfamide + Etoposide + 2 Growth Factors</arm_group_label>
    <arm_group_label>Rituximab + Ifosfamide + Etoposide + 1 Growth Factor</arm_group_label>
    <other_name>Filgrastim</other_name>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GM-CSF</intervention_name>
    <description>250 mcg/m^2 injection given every evening till the completion of apheresis.</description>
    <arm_group_label>Rituximab + Ifosfamide + Etoposide + 2 Growth Factors</arm_group_label>
    <other_name>Sargramostim</other_name>
    <other_name>Leukine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isophosphamide</intervention_name>
    <description>10 g/m^2 given intravenously continuous infusion over 72 hours.</description>
    <arm_group_label>Rituximab + Ifosfamide + Etoposide + 2 Growth Factors</arm_group_label>
    <arm_group_label>Rituximab + Ifosfamide + Etoposide + 1 Growth Factor</arm_group_label>
    <other_name>ifosfamide</other_name>
    <other_name>Ifex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Days +1 (375 mg/m^2) and +8 (1000 mg/m^2) given intravenously.</description>
    <arm_group_label>Rituximab + Ifosfamide + Etoposide + 2 Growth Factors</arm_group_label>
    <arm_group_label>Rituximab + Ifosfamide + Etoposide + 1 Growth Factor</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Apheresis</intervention_name>
    <description>Peripheral blood stem cell collection.</description>
    <arm_group_label>Rituximab + Ifosfamide + Etoposide + 2 Growth Factors</arm_group_label>
    <arm_group_label>Rituximab + Ifosfamide + Etoposide + 1 Growth Factor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically confirmed CD20 positive B-cell non-Hodgkin's lymphoma who
             are candidates for autologous stem cell transplantation.

          2. Age up to 70 years

          3. Platelet count &gt; 100,000 mm3, independent of transfusion support

          4. Absolute neutrophil count (ANC) &gt; 1500/mm3

          5. Zubrod performance status of 2 or less.

          6. Negative pregnancy test in women

          7. Less than 10% marrow involvement with lymphoma within 4 weeks of study enrollment as
             defined by bilateral bone marrow aspirations and biopsies.

          8. Should be seronegative for HIV, HTLV, hepatitis B surface antigen, hepatitis C
             antibody.

        Exclusion Criteria:

          1. Clinical or radiographic evidence of active CNS disease

          2. Severe concomitant medical or psychiatric illness

          3. Lactating or breast feeding females

          4. Less than 3 weeks from the first day of last chemotherapy

          5. Prior myeloablative therapy with autologous bone marrow or stem cell rescue

          6. Serum bilirubin &gt; 1.5 X ULN, Serum transaminases &gt; 2XULN.

          7. Serum creatinine &gt;1.6 mg/dl

          8. History of pelvic radiation

          9. Patients should not have received more than 3 prior chemotherapy regimens (excluding
             radiation)

         10. Patients should not have received more than 6 cycles of fludarabine therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chitra M. Hosing, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.T.M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2007</study_first_submitted>
  <study_first_submitted_qc>July 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2007</study_first_posted>
  <results_first_submitted>March 3, 2009</results_first_submitted>
  <results_first_submitted_qc>May 21, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 7, 2009</results_first_posted>
  <last_update_submitted>June 3, 2013</last_update_submitted>
  <last_update_submitted_qc>June 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Hodgkin's Lymphoma</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Etoposide</keyword>
  <keyword>G-CSF</keyword>
  <keyword>GM-CSF</keyword>
  <keyword>Isophosphamide</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Ifosfamide</keyword>
  <keyword>Sargramostim</keyword>
  <keyword>Leukine</keyword>
  <keyword>Filgrastim</keyword>
  <keyword>Neupogen</keyword>
  <keyword>Apheresis</keyword>
  <keyword>Stem Cell Collection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: 02/12/2004 through 07/13/2007. All participants recruited at U.T. M.D. Anderson Cancer Center and participating institutions.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Rituximab + Ifosfamide + Etoposide + 2 Growth Factors</title>
          <description>Growth Factors = granulocyte-colony stimulating factor (G-CSF) + granulocyte macrophage-colony stimulating factor (GM-CSF)</description>
        </group>
        <group group_id="P2">
          <title>Rituximab + Ifosfamide + Etoposide + 1 Growth Factor</title>
          <description>Growth Factor = granulocyte-colony stimulating factor (G-CSF)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rituximab + Ifosfamide + Etoposide + 2 Growth Factors</title>
          <description>Growth Factors = granulocyte-colony stimulating factor (G-CSF) + granulocyte macrophage-colony stimulating factor (GM-CSF)</description>
        </group>
        <group group_id="B2">
          <title>Rituximab + Ifosfamide + Etoposide + 1 Growth Factor</title>
          <description>Growth Factor = granulocyte-colony stimulating factor (G-CSF)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="84"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 20 and 39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 40 and 59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 60 and 79 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="53.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="84.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>CD34+ Cells/kg in Blood Stem Cells</title>
        <description>After blood counts return to normal, stem cell collection (takes approximately 4 hours) up to 6 sessions.</description>
        <time_frame>The process of stem cell collections take about 4 hours, 1-6 sessions may be needed.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rituximab + Ifosfamide + Etoposide + 2 Growth Factors</title>
            <description>Growth Factors = granulocyte-colony stimulating factor (G-CSF) + granulocyte macrophage-colony stimulating factor (GM-CSF)</description>
          </group>
          <group group_id="O2">
            <title>Rituximab + Ifosfamide + Etoposide + 1 Growth Factor</title>
            <description>Growth Factor = granulocyte-colony stimulating factor (G-CSF)</description>
          </group>
        </group_list>
        <measure>
          <title>CD34+ Cells/kg in Blood Stem Cells</title>
          <description>After blood counts return to normal, stem cell collection (takes approximately 4 hours) up to 6 sessions.</description>
          <units>CD34+ cells/kg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="0.7" upper_limit="73"/>
                    <measurement group_id="O2" value="10.34" lower_limit="0.14" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years and 3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rituximab + Ifosfamide + Etoposide + 2 Growth Factors</title>
          <description>Growth Factors = granulocyte-colony stimulating factor (G-CSF) + granulocyte macrophage-colony stimulating factor (GM-CSF)</description>
        </group>
        <group group_id="E2">
          <title>Rituximab + Ifosfamide + Etoposide + 1 Growth Factor</title>
          <description>Growth Factor = granulocyte-colony stimulating factor (G-CSF)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>CYTOKINE RELEASE SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>ANEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>NAUSEA/VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chitra M. Hosing, MD / Associate Professor</name_or_title>
      <organization>U.T. M.D. Anderson Cancer Center</organization>
      <phone>713-792-8750</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

